JP2006513170A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006513170A5 JP2006513170A5 JP2004553825A JP2004553825A JP2006513170A5 JP 2006513170 A5 JP2006513170 A5 JP 2006513170A5 JP 2004553825 A JP2004553825 A JP 2004553825A JP 2004553825 A JP2004553825 A JP 2004553825A JP 2006513170 A5 JP2006513170 A5 JP 2006513170A5
- Authority
- JP
- Japan
- Prior art keywords
- solution
- buffer
- mixing
- continuous
- solutions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 239000000243 solution Substances 0.000 claims description 70
- 238000000034 method Methods 0.000 claims description 66
- 238000002156 mixing Methods 0.000 claims description 44
- 238000004519 manufacturing process Methods 0.000 claims description 26
- 230000008569 process Effects 0.000 claims description 25
- 239000002253 acid Substances 0.000 claims description 23
- 239000007853 buffer solution Substances 0.000 claims description 20
- 239000000872 buffer Substances 0.000 claims description 18
- 229960000074 biopharmaceutical Drugs 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 8
- 238000004587 chromatography analysis Methods 0.000 claims description 7
- 230000009261 transgenic effect Effects 0.000 claims description 7
- 239000008366 buffered solution Substances 0.000 claims description 5
- 235000013336 milk Nutrition 0.000 claims description 5
- 239000008267 milk Substances 0.000 claims description 5
- 210000004080 milk Anatomy 0.000 claims description 5
- 230000003139 buffering effect Effects 0.000 claims description 4
- 238000004113 cell culture Methods 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims 2
- 239000002585 base Substances 0.000 description 21
- 238000010977 unit operation Methods 0.000 description 15
- 239000000047 product Substances 0.000 description 14
- 239000000126 substance Substances 0.000 description 14
- 150000007513 acids Chemical class 0.000 description 13
- 150000001875 compounds Chemical class 0.000 description 13
- 238000003860 storage Methods 0.000 description 12
- 150000003839 salts Chemical class 0.000 description 11
- 239000007788 liquid Substances 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 9
- 101000827785 Homo sapiens Alpha-fetoprotein Proteins 0.000 description 7
- 101000848653 Homo sapiens Tripartite motif-containing protein 26 Proteins 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000013461 design Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 102000013529 alpha-Fetoproteins Human genes 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 102000046101 human AFP Human genes 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 102000009027 Albumins Human genes 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102000007562 Serum Albumin Human genes 0.000 description 4
- 108010071390 Serum Albumin Proteins 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000004140 cleaning Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000813 microbial effect Effects 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000034767 Hypoproteinaemia Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000011109 contamination Methods 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 238000011194 good manufacturing practice Methods 0.000 description 3
- -1 hydrogen ions Chemical class 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 125000003010 ionic group Chemical group 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 206010065673 Nephritic syndrome Diseases 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000012062 aqueous buffer Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 238000012832 cell culture technique Methods 0.000 description 2
- 231100000481 chemical toxicant Toxicity 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 238000010924 continuous production Methods 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011143 downstream manufacturing Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 239000011236 particulate material Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 230000007096 poisonous effect Effects 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003440 toxic substance Substances 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004604 Blowing Agent Substances 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 206010013812 Duodenal atresia Diseases 0.000 description 1
- 208000023281 Fallot tetralogy Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 239000006173 Good's buffer Substances 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010019663 Hepatic failure Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 206010025476 Malabsorption Diseases 0.000 description 1
- 208000004155 Malabsorption Syndromes Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 101000827784 Rattus norvegicus Alpha-fetoprotein Proteins 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 201000010829 Spina bifida Diseases 0.000 description 1
- 208000006097 Spinal Dysraphism Diseases 0.000 description 1
- 108010017842 Telomerase Proteins 0.000 description 1
- 201000003005 Tetralogy of Fallot Diseases 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000012865 aseptic processing Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 208000027119 bilirubin metabolic disease Diseases 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 238000011095 buffer preparation Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002016 colloidosmotic effect Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000012444 downstream purification process Methods 0.000 description 1
- 238000007905 drug manufacturing Methods 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012527 feed solution Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000037671 genetically modified crops Species 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- 208000036796 hyperbilirubinemia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000014666 liquid concentrate Nutrition 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 208000007903 liver failure Diseases 0.000 description 1
- 231100000835 liver failure Toxicity 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000012492 regenerant Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 206010045458 umbilical hernia Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 210000001325 yolk sac Anatomy 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42731602P | 2002-11-18 | 2002-11-18 | |
| PCT/US2003/036718 WO2004045540A2 (en) | 2002-11-18 | 2003-11-18 | Method for continuous, automated blending of solutions from acids and bases |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006513170A JP2006513170A (ja) | 2006-04-20 |
| JP2006513170A5 true JP2006513170A5 (enExample) | 2007-01-18 |
Family
ID=32326519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004553825A Abandoned JP2006513170A (ja) | 2002-11-18 | 2003-11-18 | 酸および塩基から溶液を連続的に自動混合する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20040102380A1 (enExample) |
| EP (1) | EP1567659A4 (enExample) |
| JP (1) | JP2006513170A (enExample) |
| AU (1) | AU2003295584A1 (enExample) |
| CA (1) | CA2506317A1 (enExample) |
| WO (1) | WO2004045540A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8271139B2 (en) * | 2003-10-17 | 2012-09-18 | Asahi Kasei Bioprocess, Inc. | Multi-stage accurate blending system and method |
| US7072742B1 (en) * | 2003-10-17 | 2006-07-04 | Technikrom, Inc. | Accurate blending module and method |
| US7515994B2 (en) * | 2003-10-17 | 2009-04-07 | Technikrom, Inc. | Accurate blending module and method |
| US20070085989A1 (en) * | 2005-06-21 | 2007-04-19 | Nikon Corporation | Exposure apparatus and exposure method, maintenance method, and device manufacturing method |
| US7790040B2 (en) | 2006-08-30 | 2010-09-07 | Semba Biosciences, Inc. | Continuous isocratic affinity chromatography |
| US8807164B2 (en) * | 2006-08-30 | 2014-08-19 | Semba Biosciences, Inc. | Valve module and methods for simulated moving bed chromatography |
| EP2223925A1 (en) * | 2006-10-09 | 2010-09-01 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| JP5961112B2 (ja) * | 2009-09-25 | 2016-08-02 | ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ | 液体混合物の調製方法及びシステム |
| US9527010B2 (en) | 2009-09-25 | 2016-12-27 | Ge Healthcare Bio-Sciences Corp. | Separation system and method |
| WO2011162666A1 (en) | 2010-06-23 | 2011-12-29 | Ge Healthcare Bio-Sciences Ab | Method of preparing liquid mixtures |
| JP5824527B2 (ja) | 2010-12-07 | 2015-11-25 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | 供給物混合装置およびその使用 |
| JP6189751B2 (ja) | 2010-12-30 | 2017-08-30 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | 病原体不活性化剤としてのグリコール |
| JP2016508515A (ja) | 2013-02-13 | 2016-03-22 | ラボラトワール フランセ デュ フラクショヌマン エ デ ビオテクノロジーＬａｂｏｒａｔｏｉｒｅ Ｆｒａｎｃａｉｓ ｄｕ Ｆｒａｃｔｉｏｎｎｅｍｅｎｔ ｅｔ ｄｅｓ Ｂｉｏｔｅｃｈｎｏｌｏｇｉｅｓ | 高ガラクトシル化抗ＴＮＦ−α抗体およびその使用 |
| US10034921B2 (en) | 2013-02-13 | 2018-07-31 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Proteins with modified glycosylation and methods of production thereof |
| AU2014285971A1 (en) | 2013-07-05 | 2016-02-04 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
| WO2015104794A1 (ja) * | 2014-01-08 | 2015-07-16 | 株式会社日立製作所 | 試料前処理装置 |
| FR3038517B1 (fr) | 2015-07-06 | 2020-02-28 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Utilisation de fragments fc modifies en immunotherapie |
| WO2017188917A1 (en) * | 2016-04-25 | 2017-11-02 | Safe Foods Corporation | Antimicrobial application methods and systems with improved ph monitoring |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1329308A (en) * | 1970-09-29 | 1973-09-05 | Dahms H | Titration of chloride and bicarbonate in serum |
| US4555348A (en) * | 1984-06-28 | 1985-11-26 | Sybron Chemicals Inc. | Liquid buffer system |
| FR2578982B1 (fr) * | 1985-03-18 | 1987-03-27 | Serg Gts Sarl | Appareil automatique pour le titrage par pesees de produits liquides et procede de mise en oeuvre d'un tel appareil |
| US4833233A (en) * | 1987-08-20 | 1989-05-23 | The United States Of America As Represented By The Administrator Of The National Aeronautics And Space Administration | Human serum albumin crystals and method of preparation |
| US4907892A (en) * | 1989-02-02 | 1990-03-13 | Fuller Company | Method and apparatus for filling, blending and withdrawing solid particulate material from a vessel |
| WO1991002049A1 (en) * | 1989-08-04 | 1991-02-21 | Peter Grandics | An integrated cell culture-protein purification system for the automated production and purification of cell culture products |
| US5725871A (en) * | 1989-08-18 | 1998-03-10 | Danbiosyst Uk Limited | Drug delivery compositions comprising lysophosphoglycerolipid |
| US5537914A (en) * | 1989-10-04 | 1996-07-23 | Micro-Blend, Inc. | Beverage blending and proportioning |
| US5823669A (en) * | 1991-05-03 | 1998-10-20 | Lolco Packaging Corp. | Method for blending diverse blowing agents |
| US5340210A (en) * | 1992-02-25 | 1994-08-23 | Nalco Chemical Company | Apparatus for blending chemicals with a reversible multi-speed pump |
| US5640330A (en) * | 1995-04-18 | 1997-06-17 | Ibm Corporation | Method for analyzing pH titration data |
| US5641531A (en) * | 1995-09-28 | 1997-06-24 | Abbott Laboratories | Nutritional liquid supplement beverage and method of making same |
| US5639954A (en) * | 1995-11-13 | 1997-06-17 | Delco Electronics Corporation | Method and apparatus for automatic titration of solder flux |
| US5996650A (en) * | 1996-11-15 | 1999-12-07 | Oden Corporation | Net mass liquid filler |
| US6004508A (en) * | 1997-08-01 | 1999-12-21 | The Coca-Cola Company | Method and apparatus for super critical treatment of liquids |
| CA2335613A1 (en) * | 1998-06-25 | 1999-12-29 | Lana Janes | Ph-indicator based assay for selective enzymes |
| DE19858892A1 (de) * | 1998-12-19 | 2000-06-21 | Merck Patent Gmbh | Kontinuierliches Verfahren zur Trennung von Stoffen nach Molekülgröße |
| US6180335B1 (en) * | 1999-09-30 | 2001-01-30 | University Of New Mexico | Apparatus for detecting contamination in food products |
| RU2182505C1 (ru) * | 2001-04-18 | 2002-05-20 | Федеральная ассоциация "Двойные технологии" | Непрерывный способ детоксикации отравляющих веществ и токсичных химических соединений |
| NZ529767A (en) * | 2001-06-13 | 2005-10-28 | Taurus Hsa Llc | Purification of human serum albumin |
-
2003
- 2003-11-18 AU AU2003295584A patent/AU2003295584A1/en not_active Abandoned
- 2003-11-18 JP JP2004553825A patent/JP2006513170A/ja not_active Abandoned
- 2003-11-18 WO PCT/US2003/036718 patent/WO2004045540A2/en not_active Ceased
- 2003-11-18 EP EP03786782A patent/EP1567659A4/en not_active Withdrawn
- 2003-11-18 CA CA002506317A patent/CA2506317A1/en not_active Abandoned
- 2003-11-18 US US10/715,701 patent/US20040102380A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006513170A5 (enExample) | ||
| JP2006513170A (ja) | 酸および塩基から溶液を連続的に自動混合する方法 | |
| US12024550B2 (en) | Bioreactor arrangement and continuous process for producing and capturing a biopolymer | |
| Zhu et al. | Industrial production of therapeutic proteins: cell lines, cell culture, and purification | |
| US8506797B2 (en) | Downstream bioprocessing device | |
| TWI702226B (zh) | 治療性蛋白質藥物物質之整合連續製造 | |
| CN113490738B (zh) | 用于生产治疗性蛋白质的自动化集成连续系统和生物工艺 | |
| Judge et al. | The effect of protein impurities on lysozyme crystal growth | |
| JPH033640B2 (enExample) | ||
| US20060033222A1 (en) | Devices for introducing a gas into a liquid and methods of using the same | |
| US20220380718A1 (en) | Continuous reconstitution of process materials from solids | |
| Zhou et al. | Implementation of advanced technologies in commercial monoclonal antibody production | |
| Patel et al. | Waste valorization: Recovery of lactose from partially deproteinated whey by using acetone as anti-solvent | |
| Stephens et al. | Technical advances in the study of nutrition of marine molluscs | |
| JP4523841B2 (ja) | 生体分子の安定化のための組成物およびプロセス | |
| Luitjens et al. | Production and purification of recombinant proteins | |
| Tomazi et al. | Batch processing industries | |
| Schmidt | Process intensification in biomanufacturing driven by advances in single use technologies | |
| Aldabaibeh | Towards an improved understanding of the variables controlling crystal modification and phase transition in lysozyme crystals | |
| Cvetković | Evaluation of downstream methods for monoclonal antibodies produced from CHO cell lines | |
| EA044422B1 (ru) | Способ очистки ифр-1 | |
| Porqueras Domčnech | Monoclonal antibodies manufacture for cancer therapy | |
| Walter et al. | Concepts for disposables in biopharmaceutical manufacture | |
| Hoeks et al. | BPMSS–Lonza's Biopharmaceutical Small Scale Plant Started cGMP Manufacturing in September 2004 | |
| Scott | Preparative and Process Chromatography |